259 related articles for article (PubMed ID: 9856813)
21. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
Bronte V; Apolloni E; Ronca R; Zamboni P; Overwijk WW; Surman DR; Restifo NP; Zanovello P
Cancer Res; 2000 Jan; 60(2):253-8. PubMed ID: 10667570
[TBL] [Abstract][Full Text] [Related]
22. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
24. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128
[TBL] [Abstract][Full Text] [Related]
25. The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.
Merimsky O; Shoenfeld Y; Fishman P
Clin Rev Allergy Immunol; 1998; 16(3):227-36. PubMed ID: 9773250
[TBL] [Abstract][Full Text] [Related]
26. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis.
Hann SK; Kim JB
Yonsei Med J; 1995 Nov; 36(5):457-61. PubMed ID: 8546004
[TBL] [Abstract][Full Text] [Related]
27. Autoimmune depigmentation following sensitization to melanoma antigens.
Hurwitz AA; Ji Q
Methods Mol Med; 2004; 102():421-7. PubMed ID: 15286398
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
29. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).
Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
Clin Exp Immunol; 1998 Dec; 114(3):333-8. PubMed ID: 9844040
[TBL] [Abstract][Full Text] [Related]
30. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.
Merimsky O; Shoenfeld Y; Yecheskel G; Chaitchik S; Azizi E; Fishman P
Cancer Immunol Immunother; 1994 Jun; 38(6):411-6. PubMed ID: 8205563
[TBL] [Abstract][Full Text] [Related]
31. Melanoma-associated leukoderma - immunology in black and white?
Naveh HP; Rao UN; Butterfield LH
Pigment Cell Melanoma Res; 2013 Nov; 26(6):796-804. PubMed ID: 24010963
[TBL] [Abstract][Full Text] [Related]
32. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
33. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern SL; Morton DL
J Clin Oncol; 2002 Aug; 20(15):3242-8. PubMed ID: 12149297
[TBL] [Abstract][Full Text] [Related]
34. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
Boasberg PD; Hoon DS; Piro LD; Martin MA; Fujimoto A; Kristedja TS; Bhachu S; Ye X; Deck RR; O'Day SJ
J Invest Dermatol; 2006 Dec; 126(12):2658-63. PubMed ID: 16946711
[TBL] [Abstract][Full Text] [Related]
35. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity.
Lucchese A; Willers J; Mittelman A; Kanduc D; Dummer R
J Immunol; 2005 Nov; 175(10):7009-20. PubMed ID: 16272362
[TBL] [Abstract][Full Text] [Related]
36. New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT; Turk MJ
Oncotarget; 2011 Sep; 2(9):684-94. PubMed ID: 21911918
[TBL] [Abstract][Full Text] [Related]
37. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
Hoon DS; Yuzuki D; Hayashida M; Morton DL
J Immunol; 1995 Jan; 154(2):730-7. PubMed ID: 7814879
[TBL] [Abstract][Full Text] [Related]
38. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo.
Austin LM; Boissy RE
Am J Pathol; 1995 Jun; 146(6):1529-41. PubMed ID: 7778691
[TBL] [Abstract][Full Text] [Related]
39. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
[TBL] [Abstract][Full Text] [Related]
40. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
Höfs T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
